Source comparison
TB-500 vs BPC-157 vs Growth Hormone — Research Context Comparison
TB-500 Actin regulation, angiogenesis promotion Tendon, ligament, chronic soft tissue injuries 5mg twice weekly for 4–6 weeks, then 2–5mg weekly maintenance Animal models, limited human data Strongest evidence for vascular-poor tissue healing; no FDA approval
This comparison does not assign a generated winner or score.
- TB-500
- Actin regulation, angiogenesis promotion
- Tendon, ligament, chronic soft tissue injuries
- 5mg twice weekly for 4–6 weeks, then 2–5mg weekly maintenance
- Animal models, limited human data
- Strongest evidence for vascular-poor tissue healing; no FDA approval
- BPC-157
- Gut-brain axis modulation, VEGF upregulation, nitric oxide pathway
- Muscle tears, tendon injuries, gastrointestinal healing
- 250–500mcg daily (subcutaneous or oral)
- Primarily rat studies
- Faster subjective pain reduction; less evidence for structural healing vs TB-500
- Growth Hormone (rHGH)
- IGF-1 upregulation, protein synthesis stimulation
- Muscle hypertrophy, bone density, general recovery
- 2–4 IU daily (varies widely)
- Extensive clinical data (FDA-approved for specific conditions)
- Systemic effects beyond injury repair; higher cost; requires prescription
- Platelet-Rich Plasma (PRP)
- Autologous growth factor delivery
- Tendon, cartilage, ligament injuries
- Single or multiple injections (1–3 sessions)
- Mixed clinical trial results
- FDA-cleared procedure; efficacy debated; no pharmaceutical regulation